PRNewsWire
02 Mar 2026, 14:45 UTC · 28w ago
Verdict
Headline takes no side. We score RARE −1.00 across two claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Ultragenyx's Phase III Orbit and Cosmic studies failed to achieve statistical significance against primary endpoints for reduction in annualized clinical fracture rate.
More negative than 99% of claims this week
A securities fraud class action lawsuit has been filed against Ultragenyx alleging the company made misleading statements regarding the setrusumab drug trials.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 74% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company faces a securities fraud class action lawsuit following a 42% stock price drop after clinical trials failed to achieve statistical significance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
−38.0%
Price agrees with the score
$14.51 vs $23.39 close before publication (Feb 27) · not market-adjusted
RARE chart →
